Ono Entered into a Collaboration and Option Agreement with Cue Biopharma for CUE-401 to Treat Autoimmune and Inflammatory Diseases
Shots:
- Cue Biopharma will receive up front & is eligible to receive ~$220M in milestones upon exercise of the option rights along with royalties
- Ono to get an exclusive option to license rights globally to develop & commercialize CUE-401, a bispecific protein designed to induce & expand regulatory T cells (Tregs) while Cue Biopharma will also hold an option to develop and commercialize the product with Ono in the US
- Cue Biopharma will lead the R&D of CUE-401 while Ono will cover the R&D expenses during an option period. CUE-401 showed induction and expansion of Tregs and has the potential to address a broad range of autoimmune and inflammatory diseases in pre-clinical studies
Ref: Ono | Image: Ono
Related Post:- Ono Entered into an Option and Research Collaboration Agreement with Monash University to Discover Anti-GPCR Antibodies
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
